Group 1 - A total of 21 companies were investigated by institutions on September 29, with 14 companies specifically targeted by funds [1] - The most popular company among funds was Yongzhen Co., with 26 funds participating in the investigation [1] - Other notable companies included Borui Pharmaceutical and Ruixin Microelectronics, attracting 23 and 18 funds respectively [1] Group 2 - The companies investigated belong to various sectors, with the pharmaceutical and biological industry having the highest representation, featuring 4 companies [1] - The total market capitalization of the investigated companies included 1 company with a market cap over 500 billion and 7 companies with a market cap below 100 billion [1] - The market performance of the investigated stocks showed that 8 out of 14 companies increased in value over the past 5 days, with Shengda Resources, Weiteou, and Fangsheng Pharmaceutical leading with increases of 15.07%, 14.42%, and 8.62% respectively [1] Group 3 - Among the funds participating in the investigations, 6 stocks experienced net inflows over the past 5 days, with Fangsheng Pharmaceutical receiving a net inflow of 119 million [2] - Other companies with significant net inflows included Shengda Resources and Jinshi Resources, with net inflows of 108 million and 41.28 million respectively [2] - A detailed list of companies investigated includes their respective fund participation, latest closing prices, and recent performance metrics [2]

Core Insights - The traditional Chinese medicine sector saw a slight increase of 0.27% on September 29, with Jilin Aodong leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Stock Performance - Jilin Aodong (000623) closed at 20.40, with a rise of 6.69% and a trading volume of 477,000 shares, amounting to a transaction value of 956 million yuan [1] - Other notable performers included: - Zhongheng Group (600252) at 2.74, up 3.40% with a volume of 793,500 shares [1] - Tailong Pharmaceutical (600222) at 6.52, up 3.00% with a volume of 226,600 shares [1] - Jinhua Co., Ltd. (600080) at 7.21, up 3.00% with a volume of 125,500 shares [1] Fund Flow Analysis - The traditional Chinese medicine sector experienced a net outflow of 244 million yuan from institutional investors, while retail investors saw a net inflow of 204 million yuan [2] - The main fund inflows and outflows for specific stocks included: - Jilin Aodong had a net inflow of 91.59 million yuan from institutional investors [3] - Yunnan Baiyao saw a net inflow of 26.21 million yuan from institutional investors [3] - Taikang Group (600129) had a net inflow of 6.25 million yuan from institutional investors [3]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [1] Core Insights - The report highlights the ongoing adjustments to the National Essential Medicines List (NEML), with a focus on the potential inclusion of various traditional Chinese medicine products, which could significantly enhance growth opportunities for related companies [7][15][27] - The report emphasizes the historical context of the NEML, noting that it has undergone several revisions since its inception in 1982, with the latest version released in 2018 [5][16] - The report suggests that the demand for adjustments to the NEML is increasing, particularly for chronic disease medications and innovative domestic drugs, indicating a potential shift in the market landscape [27] Summary by Sections 1. NEML Adjustment Progress - The NEML is set to be adjusted approximately every three years, but the last update was in 2018, leading to calls for a new revision to include more chronic disease medications and innovative products [27] - The report recommends monitoring companies that may benefit from being included in the updated NEML, particularly in the traditional Chinese medicine sector [28] 2. Historical Context of NEML - The NEML was first published in 1982, with significant revisions occurring in 2009, 2012, and 2018, reflecting the government's commitment to improving public health through essential medicines [5][16] - The 2018 version of the NEML included 685 items, with a notable increase in the number of traditional Chinese medicines, indicating a growing recognition of their importance [20][21] 3. Future Outlook - The report anticipates that the upcoming adjustments to the NEML will likely favor traditional Chinese medicine products, which could lead to increased sales and market penetration for companies in this sector [26][27] - Companies like Fangsheng Pharmaceutical are highlighted for their innovative approaches and potential for rapid growth in the traditional Chinese medicine market [30][31] 4. Market Performance - In the fourth week of September 2025, the pharmaceutical and biotechnology sector experienced a decline of 2.20%, underperforming compared to the CSI 300 index [32] - The report notes that while the overall sector faced challenges, certain sub-sectors, such as other biological products, showed resilience with positive growth [38][39]

Market Overview - On September 26, the Traditional Chinese Medicine (TCM) sector declined by 0.38%, with Weikang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3828.11, down 0.65%, while the Shenzhen Component Index closed at 13209.0, down 1.76% [1] Stock Performance - Notable gainers in the TCM sector included: - *ST Changyao: Closed at 3.88, up 3.47% with a trading volume of 134,100 shares [1] - Fangsheng Pharmaceutical: Closed at 12.08, up 2.11% with a trading volume of 274,600 shares [1] - Huaren Sanjiu: Closed at 28.39, up 1.50% with a trading volume of 133,600 shares [1] - Major decliners included: - Weikang Pharmaceutical: Closed at 23.66, down 6.30% with a trading volume of 81,000 shares [2] - Zhendong Pharmaceutical: Closed at 6.57, down 4.09% with a trading volume of 518,000 shares [2] - Zhongsheng Pharmaceutical: Closed at 17.00, down 2.41% with a trading volume of 295,000 shares [2] Capital Flow - The TCM sector experienced a net outflow of 298 million yuan from institutional investors, while retail investors saw a net inflow of 396 million yuan [2] - Key stocks with significant capital flow included: - Huaren Sanjiu: Net inflow of 44.98 million yuan from institutional investors [3] - Fangsheng Pharmaceutical: Net inflow of 33.39 million yuan from institutional investors [3] - Dong'e Ejiao: Net inflow of 32.19 million yuan from institutional investors [3]

Core Viewpoint - Fangsheng Pharmaceutical has shown a positive stock performance with a year-to-date increase of 20.68% and a recent surge of 12.06% over the past five trading days, indicating strong market interest and potential growth in the pharmaceutical sector [1][2]. Financial Performance - For the first half of 2025, Fangsheng Pharmaceutical reported a revenue of 834 million yuan, a year-on-year decrease of 8.35%, while the net profit attributable to shareholders increased by 23.67% to 169 million yuan [2]. - The company has distributed a total of 689 million yuan in dividends since its A-share listing, with 444 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 33,100, with an average of 13,245 circulating shares per person, a slight decrease of 0.36% [2]. - The top ten circulating shareholders include notable institutional investors, with ICBC Medical Health Stock holding 5.40 million shares, unchanged from the previous period, and Rongtong Health Industry Flexible Allocation Mixed Fund increasing its holdings by 500,000 shares to 5 million [3]. Market Activity - On September 26, Fangsheng Pharmaceutical's stock price rose by 2.11% to 12.08 yuan per share, with a trading volume of 125 million yuan and a turnover rate of 2.42%, resulting in a total market capitalization of 5.304 billion yuan [1]. - The net inflow of main funds was 4.67 million yuan, with significant buying activity from large orders, indicating strong investor interest [1].

证券之星消息，9月24日中药板块较上一交易日下跌0.28%，维康药业领跌。当日上证指数报收于 3853.64，上涨0.83%。深证成指报收于13356.14，上涨1.8%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600222 | 太龙药业 | 6.60 | 4.27% | 21.58万 | | 1.41亿 | | 600129 | 太极集团 | 21.75 | 3.97% | 16.50万 | | 3.54Z | | 603998 | 方盛制药 | 11.83 | 3.23% | 44.30万 | | 5.23亿 | | 300181 | 佐力药业 | 18.09 | 3.02% | 17.62万 | | 3.17亿 | | 000423 | 东阿阿胶 | 48.10 | 2.69% | 10.18万 | | 4.87亿 | | 600329 | 达仁堂 | 45.08 | 2.69% | 7.64万 | | 3.43亿 | | 300534 | ...

Group 1 - The core viewpoint of the news is that Fangsheng Pharmaceutical has announced the completion of a Phase II clinical trial summary report for Zhilong Tongluo Tablets, which are indicated for the treatment of ischemic stroke recovery and related symptoms [1][2] - The clinical trial involved 240 planned participants, with 214 actually enrolled, and utilized a randomized, double-blind, placebo-controlled design to evaluate the efficacy and safety of Zhilong Tongluo Tablets [1] - The trial results indicated that Zhilong Tongluo Tablets improved neurological function and daily living abilities, showing effectiveness in treating symptoms associated with ischemic stroke, with no significant safety concerns reported [2] Group 2 - Zhilong Tongluo Tablets are classified as a Class 1 innovative traditional Chinese medicine and are currently the exclusive product of the company, with no other enterprises having obtained production approval for this product [2] - The market for traditional Chinese medicine treatments for stroke includes several products such as Naoxintong Capsules and Tongxinluo Capsules, indicating a competitive landscape [2]

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. announced the completion of the Phase II clinical trial report for its innovative traditional Chinese medicine, Zhilong Tongluo Tablets, which is aimed at treating ischemic stroke recovery [1][2]. Group 1: Basic Information - Drug Name: Zhilong Tongluo Tablets - Dosage Form: Tablets - Research Type: Phase II Clinical Trial - Clinical Approval Number: 2011L01961 - Clinical Approval Date: November 5, 2011 - Cumulative R&D Expenditure: Approximately 13.566 million RMB (unaudited) [1]. - Indication: Aims to invigorate qi and blood, dispel stasis, and is suitable for treating symptoms related to ischemic stroke recovery [1]. Group 2: Clinical Research Details - The clinical trial was conducted at seven national drug clinical trial institutions across various provinces, with a total of 240 planned participants, of which 214 were actually enrolled [2][3]. - The trial design was randomized, double-blind, and included a placebo control, with participants divided into high-dose (7.5g/day), low-dose (4.5g/day), and placebo groups, receiving treatment for 12 weeks [3]. Group 3: Clinical Research Results - Efficacy results indicated that both high and low doses of Zhilong Tongluo Tablets showed better outcomes compared to the placebo in terms of the Modified Rankin Scale, NIHSS score changes, and quality of life measures [4]. - Safety results showed no significant differences in severe adverse events among groups, with all serious adverse events related to acute stroke recurrence, indicating good safety [4]. - The low-dose group is recommended to proceed to Phase III clinical research due to comparable efficacy with the high-dose group [4]. Group 4: Market Situation - Zhilong Tongluo Tablets are classified as a Class 1 innovative traditional Chinese medicine and are currently the company's exclusive product, with no other companies having obtained production approval for this product [5]. - Other traditional Chinese medicines for treating ischemic stroke include various products with significant sales figures, indicating a competitive market landscape [5].

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. announced that its innovative traditional Chinese medicine, Zhilong Tongluo Tablets, has obtained the Phase II clinical trial summary report, indicating progress in its development for treating ischemic stroke recovery [1][3]. Group 1: Basic Information - Drug Name: Zhilong Tongluo Tablets - Dosage Form: Tablets - Research Type: Phase II Clinical Trial - Clinical Approval Number: 2011L01961 - Clinical Approval Date: November 5, 2011 - Cumulative R&D Expenditure: Approximately 13.566 million RMB (unaudited) [1][2]. - Indication: Aimed at treating ischemic stroke recovery symptoms such as numbness, pain, and fatigue [1]. Group 2: Clinical Research Details - The Phase II clinical trial was conducted across seven national drug clinical trial institutions in Tianjin, Guangxi, Liaoning, Sichuan, Heilongjiang, and Anhui, with a total of 240 planned participants, of which 214 were actually enrolled [2][4]. - The trial design was randomized, double-blind, and included a placebo control, with participants assigned to high-dose (7.5g/day), low-dose (4.5g/day), and placebo groups [4]. Group 3: Clinical Results - The trial results indicated that both high and low doses of Zhilong Tongluo Tablets showed better efficacy compared to the placebo in improving neurological function and quality of life, with no significant difference in safety across groups [4][5]. - The low-dose group demonstrated comparable efficacy to the high-dose group, suggesting it may be suitable for further Phase III clinical research [5]. Group 4: Market Context - Zhilong Tongluo Tablets are classified as a Class 1 innovative traditional Chinese medicine and are currently the company's exclusive product, with no other companies holding production approval for it [6]. - Competing traditional Chinese medicines for treating ischemic stroke include Naoxin Tong Capsules and Tongxinluo Capsules, with reported sales figures for 2024 indicating significant market presence for these products [6].

（文章来源：证券日报） 证券日报网讯 9月23日晚间，方盛制药发布公告称，2025年9月22日，公司研发的中药创新药蛭龙通络 片取得了Ⅱ期临床研究报告。 ...